ALK and non-Hodgkin lymphoma: Ensartinib in treating patients with relapsed or Refractory advanced solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic disorders with ALK or ROS1 genomic alterations (A Pediatric MATCH Treatment Trial)